A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder

One of the few combination approaches to the treatment of obsessive-compulsive disorder (OCD) with encouraging support is the addition of an antipsychotic to a serotonin reuptake inhibitor. The study consisted of a 6-week, placebo-controlled addition of olanzapine 5–10 mg (6.1 ± 2.1 mg, mean ± SD) t...

Full description

Saved in:
Bibliographic Details
Published in:Biological psychiatry (1969) 2004-03, Vol.55 (5), p.553-555
Main Authors: Shapira, Nathan A, Ward, Herbert E, Mandoki, Miguel, Murphy, Tanya K, Yang, Mark C.K, Blier, Pierre, Goodman, Wayne K
Format: Article
Language:English
Subjects:
Adult
Adult and adolescent clinical studies
Aged
Analysis of Variance
Antipsychotic
Antipsychotic Agents - administration & dosage
Anxiety disorders. Neuroses
Benzodiazepines - administration & dosage
Biological and medical sciences
Double-Blind Method
Drug Resistance
Drug Therapy, Combination
Female
Fluoxetine - administration & dosage
Humans
Male
Medical sciences
Middle Aged
nonresponders
obsessive-compulsive disorder
Obsessive-Compulsive Disorder - drug therapy
Obsessive-compulsive disorders
olanzapine
partial responders
Prospective Studies
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
serotonin reuptake inhibitor
Serotonin Uptake Inhibitors - administration & dosage
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One of the few combination approaches to the treatment of obsessive-compulsive disorder (OCD) with encouraging support is the addition of an antipsychotic to a serotonin reuptake inhibitor. The study consisted of a 6-week, placebo-controlled addition of olanzapine 5–10 mg (6.1 ± 2.1 mg, mean ± SD) to fluoxetine in OCD subjects who were partial or nonresponders to an 8-week, open-label fluoxetine trial (40 mg in 43 subjects, 20 mg in 1 subject). Both the fluoxetine-plus-olanzapine (n = 22) and fluoxetine-plus-placebo (n = 22) groups improved significantly over 6 weeks [F(3,113) = 11.64, p < .0001] according to Yale-Brown Obsessive Compulsive Scale scores with repeated-measures analysis of variance; however, the treatment × time interaction was not significant for olanzapine versus placebo addition to fluoxetine. These findings indicate no additional advantage of adding olanzapine for 6 weeks in OCD patients who have not had a satisfactory response to fluoxetine for 8 weeks, compared with extending the monotherapy trial.
ISSN:0006-3223
1873-2402
DOI:10.1016/j.biopsych.2003.11.010